We infused dobutamine into the left main coronary artery of 24 patients with severe congestive heart failure (CHF) and 8 normal subjects without hemodynamic dysfunction. The maximal +dP/dt response to intracoronary (IC) dobutamine in CHF patients was only 37% of that in normals. This decrease in maximal response was not associated with a rightshift in the EC50 for dobutamine's effect on +dP/dt, or a decrease in the affinity of myocardial beta adrenergic receptors for dobutamine determined in vitro. In nine of the CHF patients, IC dobutamine infusion was followed by IC infusion of the phosphodiesterase inhibitor milrinone, and subsequently, by a second IC infusion of dobutamine. After IC milrinone, the increase in +dP/dt caused by IC dobutamine (74 +/-10%) was significantly greater than that caused by the first infusion of dobutamine (52 +/-11%; P less than 0.003) or milrinone (42 +/-6%; P less than 0.001). Resting plasma norepinephrine was markedly elevated in CHF patients (837 +/-208 ng/liter), but not in normal subjects (142 +/-32 ng/liter); and the increase in +dP/dt caused by IC dobutamine was inversely related to resting plasma norepinephrine levels (r = -0.653; P less than 0.001). IC dobutamine caused a dose-related decrease in plasma norepinephrine (maximal effect, -160 +/-31 ng/liter; P less than 0.001). Thus, (a) the maximal inotropic response to […] 
Introduction
Stimulation of myocardial beta adrenergic receptors causes activation of adenylate cyclase, and consequently, increased accumulation of adenosine 3',5'-monophosphate (cAMP), which is thought to augment myocardial contractility by increasing the influx of calcium through voltage-dependent channels (1) . In myocardium from patients with severe congestive heart failure (CHF),' Bristow et al. have shown that the density of beta adrenergic receptors is decreased, as are the activation of adenylate cyclase and the development of contractile force in response to isoproterenol or dobutamine (2) (3) (4) . Nevertheless, there is evidence that myocardium from patients with severe CHF responds normally to calcium and cAMP (2) (3) (4) (5) (6) (7) . These important observations have implications regarding the pathophysiology and therapy of CHF, and raise several relevant questions. (a) What is the in vivo functional hemodynamic consequence of beta adrenergic desensitization in patients with CHF? (b) Can the hemodynamic sequelae of beta adrenergic desensitization be overcome at high levels of receptor stimulation? (c) Can the myocardial response to beta adrenergic stimulation be restored by inhibiting the degradation of cAMP? (d) Is there a relationship between the level of basal sympathetic nervous system activation, as reflected by plasma catecholamines, and the degree of beta adrenergic desensitization?
Recently, we found that the positive inotropic and hemodynamic effects caused by the myocardial actions of milrinone, a phosphodiesterase inhibitor, could be quantitated by direct intracoronary (IC) drug infusion (8) . This approach allows isolation of the myocardial actions ofthe infused agent, the precise definition of dose-response relationships, frequently at drug concentrations greater than those that can be achieved during systemic infusion, and the use ofleft ventricular +dP/dt as a simple, quantifiable measure of the positive inotropic response to the infused drug. In a prior report (9), we described the differential positive inotropic responses to an IC infusion of the beta adrenergic agonist dobutamine (10) to patients with and without severe congestive heart failure. We now report the detailed dose-response relationships for the positive inotropic and hemodynamic effects of IC dobutamine infusion to 24 patients with severe CHF and 8 subjects without significant myocardial dysfunction; and the use of this methodology as an approach to the aforementioned questions.
Methods
Study population. The study population consisted of 32 subjects and was divided into two groups. One group ("normals," n = 8) had no evidence of significant CHF. These patients (three males, five females; 1 . Abbreviations used in this paper: CHF, congestive heart failure; D5W, 5% dextrose in water; dP/dt, derivative of pressure with respect to time; IC, intracoronary; IPIN, iodopindolol; LV, left ventricular. mean age±SEM, 52±2 yr) had normal baseline hemodynamic function at the time of study (Figs. 3 and 4) . None had a history ofcongestive heart failure symptoms, exhibited cardiomegaly on chest x-ray, or had been treated for congestive heart failure. Seven were receiving no cardiac medications before the time of study, and one received a beta adrenergic blocking drug until the night before study for a chest pain syndrome. The other group ("CHF," n = 24) corn;lsted ofpatients with idiopathic (n = 8) or ischemic (n = 16) dilated cardiomyopathy who were referred because of severe New York Heart Association functional class III or IV CHF despite treatment with digitalis, diuretics, and vasodilators in all cases. There were 20 males and 4 females (mean age, 59±2 yr). The mean left and right ventricular ejection fractions by radionuclide angiography were 0.15±0.02 and 0.31±0.03, respectively. All CHF patients received digitalis and diuretics up to and including the day before study, whereas vasodilators were withheld for at least 48 h before study. No subject had symptomatic coronary artery disease, documented myocardial infarction within the previous 3 mo or uncorrected valvular heart disease. Figure 1 . Relative peripheral and coronary artery concentrations of dobutamine during intravenous and IC infusion to patients with New York Heart Association functional class III and IV CHF. (A) Concentration of dobutamine measured in plasma (-) and estimated in the left main coronary artery (o) during IC infusion. The left main coronary artery concentration of dobutamine was calculated based on an assumed blood flow of 125 ml/min (13) . (B) Measured plasma dobutamine concentration in 17 patients with New York Heart Association functional class III and IV CHF during intravenous drug infusion.
to 0.831 jsg/liter; mean = 0.132±0.059 ag/liter), the contribution of dopamine to the overall dobutamine determination is minimal. The dobutamine standard curve using this method was linear from 2.5 to 250 ug/liter.
Intracoronary dobutamine infusion. After placement of catheters, baseline hemodynamic conditions were taken as the means of two consecutive sets of hemodynamic measurements separated by at least 10 min and differing by < 10%. Subsequently, 5% dextrose in water (DSW), the vehicle for IC drug infusion, was infused into the left main coronary artery for 5 min. At an infusion rate (4 ml/min) that exceeded the maximum infusion rate used for the subsequent drug infusions, D5W had no effect on +dP/dt (Fig. 2) or any of the hemodynamic measurements. Dobutamine diluted in D5W was then infused with upward titration ofthe infusion rate at 5-min intervals according to the following schedule: 2.5, 5, 12.5, 25, 50, 100, and 200 sg/min. Hemodynamic measurements were made during the fifth minute of each infusion period, and the upward titration was continued until the 200-,ug/ min infusion rate was achieved or there was evidence of an adverse effect such as excessive tachycardia, increased ventricular ectopic activity, or unpleasant palpitations.
Assuming a left main coronary artery blood flow of 125 ml/min (13), the approximate concentration of dobutamine in the coronary artery would range from 0.066 to 5.30 uM over infusion rates ranging from 2.5 to 200 ,ug/min. Peripheral arterial dobutamine concentration was measured in 11 patients during IC dobutamine infusion (Fig. 1 a) , and compared to that in 17 previously reported patients with a similar degree ofCHF (14) during intravenous dobutamine (Fig. 1 B) . During intravenous dobutamine infusion, peripheral dobutamine concentrations ranged from 17±1 to 162±27 ug/liter at intravenous infusion rates of 2 to 14 pg/kg per min (Fig. 1 B) , in good agreement with the previous report ofLeier et al. (15) . At an IC infusion rate of25 ,g/min, the estimated IC dobutamine concentration is 200 ,ug/liter, a level similar to or greater than that achieved during intravenous drug infusion at the maximum approved rate of 14 ;tg/kg per min (Fig. 1 B) . At this IC infusion rate (i.e., 25 ;tg/min) peripheral dobutamine was barely detectable (6±2 ug/liter), and was substantially less (P < 0.001) than the concentration of drug achieved with a 2-,ug/kg per min intravenous drug infusion ( 17±1IAg/liter). A plateau in the +dP/dt response generally occurred by the end ofthe second minute, and in all cases by the end ofthe fourth minute ofIC dobutamine infusion; and was stable for the remainder of each 5-min infusion period. After discontinuing baseline. Baseline +dP/dt was 1,446±87 and 886±97 mmHg/s in patients without and with CHF, respectively. The increase in +dP/dt over baseline was significant at all infusion rates in both groups. At 5 ,ug/min and all higher infusion rates, the increase was greater in patients without CHF. *P < 0.01 for normal vs ( 18) .
Results
Effect ofIC dobutamine infusion on +dP/dt (Fig. 2) sure, or systemic vascular resistance; and at the peak infusion rate evaluated, there was a small increase in mean arterial pressure (+4±1 mmHg, P < 0.02 vs. D5W) and a small decrease in systemic vascular resistance (-287±76 dyn-s-cm-5; P < 0.01).
The 25-gg/min infusion rate caused -4±1 and -5±1 mmHg decreases in left ventricular end-diastolic pressure in normals and CHF patients, respectively (P < 0.0025 for both).
By contrast, stroke volume index (+6+1 ml/m2; P < 0.001) and stroke work index (+6±1 g.m/M2; P < 0.001) were increased by IC dobutamine (25 ,ug/min) in CHF patients, but not in normal subjects (P = NS for both) (Figs. 3 and 4) . All hemodynamic effects returned to control values during repeat D5W infusion. Effect ofIC milrinone on the response to IC dobutamine. In nine CHF patients, the initial IC dobutamine infusion was followed by the IC infusion of milrinone, and subsequently, by a second infusion of dobutamine. The initial IC dobutamine infusion (mean infusion rate, 61±16 gg/min) resulted in an increase in +dP/dt in all subjects (mean increase, 52±11%; P < 0.002 vs. D5W) (Fig. 5) . There was no significant change in heart rate, mean arterial pressure, or systemic vascular resistance, but left ventricular function was improved as indicated by an increase in stroke work index and a decrease in left ventricular end-diastolic pressure (P < 0.01 vs. D5W for both) (Fig. 6 ). After discontinuation of dobutamine, +dP/dt, stroke work index and left ventricular end-diastolic pressure all returned to within 5% of the initial D5W baseline values (Figs. 5 and 6).
Intracoronary milrinone infusion resulted in a 42±6% increase in +dP/dt (Fig. 5 ) which was associated with significant improvement in left ventricular function as evidenced by an increase in stroke work index and a decrease in left ventricular end-diastolic pressure (P < 0.01 for both) (Fig. 6 ), but no significant change in heart rate, mean arterial pressure or systemic vascular resistance. Immediately following discontinua- tion of IC milrinone, IC dobutamine was infused again at the same rate as before IC milrinone, and +dP/dt and hemodynamics were measured between 3.5 and 5.0 min later. In every patient, the increase in +dP/dt during the second dobutamine infusion was greater than during the first infusion (mean increase, 74±10%; P < 0.003 vs. first dobutamine infusion), and also, was greater than during the immediately preceding IC milrinone infusion (P < 0.001) (Fig. 5 ). Heart rate, mean arterial pressure and systemic vascular resistance were not significantly different than during the first dobutamine or milrinone infusions (P = NS for all). Compared with the hemodynamic effects of the immediately preceding IC milrinone infusion, left ventricular end-diastolic pressure was lower (P < 0.05) and stroke work index was higher (P < 0.05), indicating a further improvement in left ventricular function (Fig. 6 ).
In five other CHF patients, the effect of a second IC dobutamine infusion was evaluated without an intervening IC milrinone infusion (Fig. 5) . Left ventricular +dP/dt increased from 643±98 to 895±129 mmHg/s (P < 0.003) during the first dobutamine infusion (mean infusion rate, 65±15 Ag/min), Fig. 3 , the effects of the 25-gg/min (25) x . q and returned to 641±96 mmHg/s after the infusion was stopped. The +dP/dt increased to 926± 148 mmHg/s (P = NS vs. first dobutamine infusion) in response to a second IC dobutamine infusion at the same infusion rate as the first infusion. Relationship between plasma catecholamines and the response to IC dobutamine. Supine resting plasma norepinephrine and epinephrine concentration sampled during the initial D5W control period were 142±32 and 54±19 ng/liter in normal subjects. In CHF patients, norepinephrine (837±208 ng/ liter; range 136-3972 ng/liter) and epinephrine (139±29 ng/ liter; range, 31-309 ng/liter) were markedly elevated at rest and significantly higher than in normals (P < 0.001 for norepinephrine; P < 0.03 for epinephrine). In CHF patients, neither norepinephrine nor epinephrine correlated significantly with heart rate, mean arterial pressure, left ventricular end-diastolic pressure, stroke volume index, cardiac index, or stroke work index (P > 0.10 for all).
The increase in +dP/dt in response to IC dobutamine (25 Ag/min) ranged from 49 to 148% in normals, and from 0 to 73% in CHF patients; and was inversely related to resting plasma norepinephrine (r = -0.653, P < 0.001 for all patients; r = 0.615, P < 0.001 for CHF patients only) (Fig. 7) . There was no significant relationship between resting epinephrine and the +dP/dt response to IC dobutamine (r = -0.300; P = 0.260 for all patients; r = -0.378; P = 0.230 for CHF patients only). In 11 ofthe patients with CHF, plasma norepinephrine was determined at each IC dobutamine infusion rate. Baseline plasma norepinephrine (518±97 ng/liter) was stable over the 30-min control period (c-1, c-2, and D5W), but decreased progressively during IC dobutamine infusion, with a maximum decrease of 160±31 ng/liter (P < 0.001 vs. D5W) at the peak dobutamine infusion rate (Fig. 8) . Norepinephrine returned to within 5% of the initial baseline value 10 min after discontinuation of IC dobutamine infusion (P < 0.001 vs. peak dobutamine) (Fig. 8) .
Discussion
The density of beta adrenergic receptors is decreased in the myocardium of patients with severe CHF (2-4). However, the physiologic consequence of this decrease in total beta adrenergic receptor number is not evident a priori since regulation of the beta adrenergic pathway can also involve alterations in the affinity of beta adrenergic receptors for agonist and the degree of coupling to adenylate cyclase (19, 20) , and may be in- Fig. 2 A, it can be seen that the EC50's for dobutamine's effect on +dP/dt are very similar in CHF patients and normal subjects. This apparent lack ofa rightshift in CHF patients is strengthened by the fact that a maximal effect was not achieved in normal individuals, and therefore the true ECQ0 in normal subjects is probably further to the right that that estimated from Fig. 2 A. Only one prior in vivo study has compared the positive inotropic responses to dobutamine in patients with and without CHF (3). Our data confirm the finding in that study of a substantial decrease in the inotropic response to dobutamine in CHF patients, and in addition, provide new information regarding the relative importance of a decrease in the maximal amplitude of response versus a shift in EC50. The radioligand binding data further suggest that the decreased efficacy of dobutamine is not due to a decrease in beta adrenergic receptor affinity for dobutamine in CHF patients. Our findings are also consistent with in vitro observations by Bristow et al. in myocardium from CHF patients showing that the dose-response curves for isoproterenol-stimulated adenylate cyclase activation and contraction were shifted downward, without a rightward shift in EC5o (2) .
A decrease in the maximal physiologic response to dobutamine (i.e., decreased efficacy) without a change in EC50 (i.e., potency) may be due to a decrease in beta adrenergic receptor number, other abnormalities of the beta adrenergic receptor pathway, such as a decreased quantity and/or function of the Intracoronary Dobutamine guanine nucleotide regulatory protein (N5) (22) (23) (24) , or an absolute reduction in the ability of contractile elements to respond to cyclic AMP or calcium. The latter possibility is unlikely to explain our data, since (a) pretreatment with the phosphodiestase inhibitor milirinone substantially increased the positive inotropic response to dobutamine in CHF patients, thus indicating that a further positive inotropic response is possible; and (b) in vitro and in vivo studies have shown a selective loss of the biochemical and contractile responses to beta adrenergic receptor stimulation without a reduction in the responses to digitalis, calcium or cyclic AMP (3, 5-7).
Although it is not necessary to postulate a defect other than a decrease in beta adrenergic receptor density, we can not exclude the role of an abnormality in the quantity and/or function of N, or the catalytic unit of adenylate cyclase. However, in vitro data indicate that the contractile responses to histamine and forskolin are normal in myocardium from CHF patients (2, 6, 7). The observation that a decrease in maximal response to dobutamine is not associated with a rightshift in the dose-response relationship suggests that operationally there is little or no receptor reserve in the beta adrenergic response to dobutamine. As stressed by Kenakin (21), this observation does not necessarily indicate the absence of "spare" beta adrenergic receptors, and may not be generalized for other agonists. However, this conclusion is consistent with that of Bristow et al., which was based on the agreement between the magnitudes of decrease in beta adrenergic receptor density and maximum isoproterenol-stimulated contraction and adenylate cyclase activation in vitro in CHF myocardium (2) . Taken together, these observations indicate that the reduced inotropic response to beta adrenergic stimulation can not be overcome fully even by high concentrations of dobutamine.
Radioligand binding and physiologic data suggest that dobutamine may interact not only with beta-1 adrenergic receptors, but also with alpha-l and beta-2 adrenergic receptors (25) (26) (27) . However, in rat myocardium the interaction with beta-2 adrenergic receptors is of low affinity and not influenced by guanine nucleotides (25) . Thus, although physiologically coupled beta-2 adrenergic receptors are present in human myocardium (4) , it is uncertain whether dobutamine acts as an agonist at these receptors. The role of alpha-1 adrenergic receptors in mediating a positive inotropic response in human myocardium is also unresolved (28, 29) . However, preliminary data from our laboratory fail to show a significant effect of the alpha adrenergic antagonist phentolamine on the +dP/dt response to IC dobutamine infusion in CHF patients (30) . Thus, we feel that the action of dobutamine in this study is primarily due to stimulation of myocardial beta adrenergic receptors. In view of the recent demonstration of a significant beta-2 adrenergic receptor-mediated contractile response in human myocardium, particularly in the presence of beta-l adrenergic receptor desensitization due to CHF (4), it is possible that the effect of dobutamine does not reflect the full beta adrenergic potential (i.e., beta-1 plus beta-2) of the myocardium in such patients.
These data provide evidence that the positive inotropic action ofthe phosphodiesterase inhibitor milrinone in patients with severe CHF is complementary to that of the beta adrenergic agonist, dobutamine, and that the combined effects of milrinone and dobutamine result in a significantly greater improvement in hemodynamic performance than either alone.
Thus, in every subject the increase in +dP/dt with IC dobutamine immediately following IC milrinone was greater than that caused by either dobutamine or milrinone alone. Milrinone acts primarily by inhibition by phosphodiesterase (31, 32), thereby causing an increase in the accumulation of myocardial cyclic AMP. It is probable that milrinone potentiated the positive inotropic response to dobutamine by causing a greater accumulation of cyclic AMP in response to any given degree ofbeta adrenergic receptor stimulation by dobutamine. Our findings are consistent with in vitro data. For instance, the positive inotropic effect of norepinephrine on rabbit papillary muscle is potentiated by the phosphodiesterase inhibitor theophylline (33) . Likewise, the positive inotropic response of guinea pig papillary muscle to isoproterenol is potentiated when isoproterenol is given at the peak of a minimally effective concentration of milrinone or after prolonged incubation with milrinone (34) . Only one other study has addressed this important issue in vivo in patients with CHF (35) . Our data and conclusion are consistent with those of Gage et al. (35) who showed that the +dP/dt response to intravenous dobutamine was greater in the presence of intravenous amrinone. In addition, the IC infusion method allows two further conclusions. First, the effect of milrinone is due to an increase the maximal amplitude of response to dobutamine, since the 74% increase in +dP/dt to dobutamine after milrinone was substantially and consistently greater than the 52% maximal response to dobutamine alone. Second, due to the design of our study, the further improvement in left ventricular pump function caused by IC dobutamine following IC milrinone, as reflected by the relationship between stroke work index and left ventricular end-diastolic pressure, can be attributed entirely to the direct actions of the two agents on myocardial systolic and/or diastolic (36) function. Although Gage et al. (35) demonstrated that the +dP/dt response to dobutamine was greater in the presence of intravenously administered amrinone, the actual contribution of this positive inotropic action to the overall hemodynamic effect of the combination of systemic dobutamine and amrinone could not be determined, since systemic amrinone also exerts a substantial vasodilator action which, in and of itself, could cause a significant hemodynamic improvement (37).
We used +dP/dt as a measure of the positive inotropic effect of dobutamine. This measurement can also be influenced by changes in preload, afterload, and heart rate. However, by using the direct intracoronary infusion method, we were able to avoid significant changes in heart rate or mean arterial pressure. Interestingly, left ventricular end-diastolic pressure decreased during intracoronary infusion of both dobutamine and milrinone. Since, as shown in Fig. 1 A, the intracoronary infusion method avoids significant peripheral levels of the infused drug, this effect may be due to a direct drug-induced improvement in myocardial relaxation (36) , possibly due to increased cAMP levels, and/or to improved forward pump function. A drug-induced decrease in left ventricular end-diastolic pressure theoretically could have attenuated the apparent magnitude of the positive inotropic response. However, it is unlikely that this change in left ventricular end-diastolic pressure significantly affected the measurement of +dP/dt in this study, since in a prior study of CHF patients with a comparable degree of hemodynamic compromise, we found that lowering left ventricular end-diastolic pressure to a similar degree with nitroprusside had no significant effect on +dP/dt (11) . Alternatively, it has been shown that at least one class of positive inotropic agents, the phosphodiesterase inhibitors, can increase left ventricular volume despite lowering end-diastolic pressure (38) . Since we did not assess the effect of dobutamine on left ventricular volume, we cannot exclude the possibility that drug-induced changes in preload contributed to the observed changes in +dP/dt.
The mechanism responsible for a decrease in myocardial beta adrenergic receptors and responsiveness in CHF is not known. By analogy to a large number of in vitro studies, it has been suggested that beta adrenergic desensitization in heart failure is a result of increased sympathetic nervous system activity (39) . This hypothesis, however, has not been tested directly in patients. Fowler et al. noted an inverse correlation between beta adrenergic receptor density and the concentration of catecholamines in the coronary sinus of CHF patients (3). We previously observed that the positive inotropic response to intravenous dobutamine was attenuated relative to the effect of milrinone, and that the attenuation was most marked in the CHF patients in whom hemodynamic dysfunction and plasma norepinephrine elevation were more marked ( 14) . In a small group of CHF patients we previously observed a weak inverse relationship between circulating norepinephrine and the +dP/dt response to IC dobutamine in CHF patients (9) . In the present, larger population this correlation continues to be significant, and therefore further supports a role of sympathetic nervous system activation in determining the physiologic beta adrenergic responsiveness of CHF patients. The relatively weak correlation may reflect the indirect relationship between circulating catecholamines and sympathetic nervous system activity, or may be due to the participation of other factors in the regulation of beta adrenergic receptor responsiveness.
In contrast to some prior studies, we did not find a significant correlation between circulating catecholamines and several measures of hemodynamic function. This is most likely a result of the relatively homogeneous hemodynamic status of our CHF patients. However, a novel observation in this study is that IC dobutamine caused a significant and rapid decrease in circulating plasma norepinephrine. Since the hemodynamic effects of IC dobutamine can only be attributed to improved myocardial function, this finding strongly suggests that despite the poor correlation between catecholamines and hemodynamic measures for the whole group, there is an important relationship between acute changes in hemodynamic function and sympathetic nervous system tone in individual patients.
The findings of this study have potential clinical importance. First, they indicate that in patients with severe CHF, the hemodynamic consequences of myocardial beta adrenergic receptor desensitization can not be overcome fully by high doses of dobutamine. Second, the ability of milrinone to increase the maximal amplitude of response to dobutamine suggests that an important action of phosphodiesterase inhibitors such as milrinone may be to ameliorate, partially, the consequences of beta adrenergic receptor desensitization; and provides a rationale for the combined administration of a beta adrenergic agonist and a phosphodiesterase inhibitor to patients with severe CHF. Finally, since there is an inverse relationship between circulating catecholamines and the severity of the physiologic desensitization to dobutamine's positive inotropic effect, the data support the notion that therapies that reduce sympathetic nervous system activity and/or reduce beta adrenergic receptor stimulation could lead to a decrease in beta adrenergic desensitization (40) .
